Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CIK cells in metastatic urogenital tumors
NCT05108077Phase 2Unknown
- Start
- Mar 2022
- Primary completion
- Dec 2023
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 2, open-label trial of unmodified CIK in bladder cancer and renal cell carcinoma (RCC) (2 arms). Primary endpoints: Relapse-free survival at 1 year and Adverse effects associated with the therapy at 1 month. Status: unknown.
02
Drugs
unmodified CIK
03
Conditions
bladder cancerrenal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT05108077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05108077.